Elite Pharmaceuticals Inc (ELTP) stock
ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$0.25−0.00 (-1.37%)
Close on Oct 19, 2026Market cap $283.02MP/E 5.0Yield –
Elite Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Elite Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was $19.04M, down 0.2% year over year. For fiscal 2026 it was $23.75M, up 218.5% from the year before. The highest annual figure on record is $23.75M in fiscal 2026.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $23.75M | +218.5% |
| FY2025 | Mar 31, 2025 | $7.46M | – |
| FY2024 | Mar 31, 2024 | -$3.24M | -196.9% |
| FY2023 | Mar 31, 2023 | $3.34M | -48.7% |
| FY2022 | Mar 31, 2022 | $6.51M | +103.8% |
| FY2021 | Mar 31, 2021 | $3.19M | – |
| FY2020 | Mar 31, 2020 | -$1.79M | – |
| FY2019 | Mar 31, 2019 | -$6.79M | – |
| FY2018 | Mar 31, 2018 | -$4.81M | – |
| FY2017 | Mar 31, 2017 | -$7.88M | – |
| FY2016 | Mar 31, 2016 | -$2.77M | – |
| FY2015 | Mar 31, 2015 | -$15.10M | – |
| FY2014 | Mar 31, 2014 | -$4.22M | – |
| FY2013 | Mar 31, 2013 | -$1.69M | – |
| FY2012 | Mar 31, 2012 | -$394.08K | -125.4% |
| FY2011 | Mar 31, 2011 | $1.55M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $10.07M | -31.8% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $9.15M | +133.4% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$5.28M | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $5.10M | +250.4% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $14.78M | +369.9% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $3.92M | +86.6% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$1.06M | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $1.46M | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $3.14M | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $2.10M | -29.3% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -$2.39M | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -$235.94K | -115.8% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -$2.71M | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $2.97M | +84.9% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -$567.88K | -118.7% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $1.50M | +872.4% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$557.52K | -132.5% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $1.61M | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $3.03M | +145.6% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $153.79K | -91.9% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $1.72M | +112.5% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$749.37K | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $1.24M | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $1.90M | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $807.42K | +328.9% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -$1.21M | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -$312.16K | – |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -$463.80K | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $188.27K | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$2.14M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -$1.27M | – |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -$1.68M | – |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -$1.71M | – |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -$1.01M | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -$478.15K | – |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -$2.23M | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -$1.09M | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | -$4.08M | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | -$726.44K | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | -$2.32M | – |
See a number that looks wrong?